Pharmacological potential of Angelica sinensis against invokana-induced bone effects in diabetic rats
Keywords:
Osteoporosis, Diabetes mellitus, Angelica sinensis, CanagliflozinAbstract
The study evaluated the effect of Angelica sinensis root aqueous extract (A. sinensis) on bone loss induced by Canagliflozin (CGF) in streptozotocin (STZ)-induced diabetic rats. A total of five groups, each comprising six Wistar albino rats, were used: control (vehicle), diabetic control (STZ), A. sinensis alone, CGF alone, and CGF + A. sinensis. Treatments were administered once daily via gastric gavage for 35 days. Results showed that bone mineral density (BMD) in treated groups was higher than in controls. Diabetic rats receiving A. sinensis exhibited significantly elevated insulin and osteocalcin levels compared to diabetic controls. These findings suggest that A. sinensis may exert preventive or therapeutic effects against diabetes-associated bone loss, likely through inhibition of bone turnover. Overall, the results support the potential role of A. sinensis as an adjunct therapy for managing bone loss in diabetic conditions and postmenopausal osteoporosis.
References
Banskota AH, Nguyen NT, Tezuka Y, Nobukawa T, Kadota S. Hypoglycemic effects of the wood of Taxus yunnanensis on streptozotocin-induced diabetic rats and its active components. Phytomedicine. 2006;13:109-14.
Krishnaraju V, et al. Taxus yunnanensis extract enhances bone formation in streptozotocin-induced diabetic rats. Asian J Res Pharm Sci Biotechnol. 2021;9(1):92-7.
Lim DW, Kim YT. Anti-osteoporotic effects of Angelica sinensis (Oliv.) Diels extract on ovariectomized rats and its oral toxicity in rats. Nutrients. 2014;6(10):4362-72.
Voelker R. Diabetes drug poses bone risks. JAMA. 2015;314(15):1554.
Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157-66.
Abdul-Majeed S, Mohamed N, Soelaiman IN. Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. Evid Based Complement Alternat Med. 2012;2012:960742.
Lee YJ, Hong JY, Kim SC, Joo JK, Na YJ, Lee KS. Association between oxidative stress and bone mineral density according to menopausal status of Korean women. Obstet Gynecol Sci. 2015;58(1):46-52.
Zhukouskaya VV, Eller-Vainicher C, Shepelkevich AP, Dydyshko Y, Cairoli E, Chiodini C. Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice. J Endocrinol Invest. 2015;38(9):941-50.
Abuohashish HM, AlRejaie SS, AlHosaini KA, Parmar MY, Ahmed MM. Alleviating effects of morin against experimentally induced diabetic osteopenia. Diabetol Metab Syndr. 2013;5(1):5.
Song SH, Zhai YK, Li CQ, Yu Q, Lu Y, Zhang Y, et al. Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro. Bone Rep. 2016;5:262-73.
Gundberg CM, Lian JB, Booth SL. Vitamin K dependent carboxylation of osteocalcin: friend or foe? Adv Nutr. 2012;3(2):149-57.
Kaddam IM, Iqbal SJ, Holland S, Wong M, Manning D. Comparison of serum osteocalcin with total and bone-specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget’s disease of bone. Ann Clin Biochem. 1994;31(4):327-30.
Cheung CL, Tan KC, Lam KS, Cheung BM. Relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: a structural equation modelling approach. J Clin Endocrinol Metab. 2013;98(9):3856-63.
Ye Y, Zhao C, Liang J, Yang Y, Yu M, Qu X. Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk. Front Pharmacol. 2019;9:1517.
